GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CKD Bio Corp (XKRX:063160) » Definitions » Cyclically Adjusted Revenue per Share

CKD Bio (XKRX:063160) Cyclically Adjusted Revenue per Share : ₩26,968.60 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is CKD Bio Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CKD Bio's adjusted revenue per share for the three months ended in Mar. 2024 was ₩8,297.385. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩26,968.60 for the trailing ten years ended in Mar. 2024.

During the past 12 months, CKD Bio's average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of CKD Bio was 5.80% per year. The lowest was 1.90% per year. And the median was 3.40% per year.

As of today (2024-06-05), CKD Bio's current stock price is ₩22350.00. CKD Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₩26,968.60. CKD Bio's Cyclically Adjusted PS Ratio of today is 0.83.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CKD Bio was 4.45. The lowest was 0.73. And the median was 1.06.


CKD Bio Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for CKD Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CKD Bio Cyclically Adjusted Revenue per Share Chart

CKD Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22,721.90 22,605.50 23,696.10 25,260.90 26,756.50

CKD Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25,754.90 26,018.60 26,691.90 26,756.50 26,968.60

Competitive Comparison of CKD Bio's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, CKD Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CKD Bio's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CKD Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CKD Bio's Cyclically Adjusted PS Ratio falls into.



CKD Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CKD Bio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8297.385/118.8477*118.8477
=8,297.385

Current CPI (Mar. 2024) = 118.8477.

CKD Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4,982.923 99.353 5,960.655
201409 4,867.763 99.608 5,807.992
201412 4,616.373 99.098 5,536.391
201503 4,496.264 99.720 5,358.711
201506 5,267.087 100.050 6,256.683
201509 5,008.683 100.110 5,946.164
201512 5,031.871 100.220 5,967.135
201603 5,347.604 100.560 6,320.112
201606 5,141.168 100.790 6,062.268
201609 5,462.436 101.460 6,398.561
201612 5,040.432 101.560 5,898.422
201703 5,575.026 102.850 6,442.188
201706 5,686.168 102.610 6,585.986
201709 5,350.724 103.490 6,144.760
201712 5,334.618 102.990 6,156.006
201803 5,710.169 104.100 6,519.121
201806 5,730.940 104.130 6,540.949
201809 6,044.085 105.650 6,799.106
201812 5,632.074 104.350 6,414.557
201903 5,807.997 104.490 6,606.059
201906 6,115.631 104.880 6,930.098
201909 6,491.194 105.200 7,333.303
201912 8,698.772 105.120 9,834.751
202003 5,645.820 105.540 6,357.710
202006 6,452.611 104.870 7,312.654
202009 6,062.930 106.200 6,784.984
202012 4,876.836 105.765 5,480.060
202103 6,106.833 107.357 6,760.451
202106 6,829.980 107.579 7,545.436
202109 6,922.450 108.759 7,564.576
202112 6,065.101 109.676 6,572.274
202203 8,559.523 111.806 9,098.630
202206 6,681.212 114.083 6,960.266
202209 6,852.166 114.831 7,091.831
202212 6,365.503 115.200 6,567.049
202303 7,965.119 116.550 8,122.174
202306 7,105.409 117.140 7,209.000
202309 7,718.351 119.111 7,701.276
202312 6,440.574 118.848 6,440.574
202403 8,297.385 118.848 8,297.385

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


CKD Bio  (XKRX:063160) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CKD Bio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=22350.00/26968.6
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CKD Bio was 4.45. The lowest was 0.73. And the median was 1.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CKD Bio Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of CKD Bio's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CKD Bio (XKRX:063160) Business Description

Industry
Traded in Other Exchanges
N/A
Address
368 Chungjeongno 3-ga, Seodaemun-gu, Seoul, KOR, 120-756
CKD Bio Corp is engaged in manufacturing and distribution of pharmaceutical materials and medicines. Its products portfolio include antibiotic, lactamase inhibitors, antituberculosis, antidiabetics, immunosuppressants, antihyperlipidemics, intermediates, and probiotics.

CKD Bio (XKRX:063160) Headlines

No Headlines